» Articles » PMID: 35566780

Are Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 Useful As Markers in Diagnostic Management of Children with Newly Diagnosed Ulcerative Colitis?

Overview
Journal J Clin Med
Specialty General Medicine
Date 2022 May 14
PMID 35566780
Authors
Affiliations
Soon will be listed here.
Abstract

Matrix Metaloproteinase-9 (MMP-9) and Tissue Inhibitor of Metaloproteinase-1 (TIMP-1), enzymes involved in tissue remodelling, have been previously reported to be overexpressed in the colonic mucosa of patients with Ulcerative colitis (UC). The aim of this study was to determine the relation of MMP-9 and TIMP-1 with UC phenotypes, the disease activity index and routinely tested inflammatory markers in newly diagnosed paediatric patients. The study group comprised 35 children diagnosed with UC and 20 control groups. Serum and faecal concentrations of MMP-9 and TIMP-1 were estimated using enzyme-like immunosorbent assay kits and correlated to the disease activity index (Paediatric Ulcerative Colitis Activity Index, PUCAI), UC phenotype (Paris Classification), inflammatory markers and endoscopic score (Mayo score). Children with UC presented with significantly higher serum and faecal concentrations of studied markers compared to the control group. Both serums, MMP-9 and TIMP-1, were higher in children with more extended and severe lesions in the colon. Furthermore, serum MMP-9 correlated with the Mayo score, Paris classification and C-reactive protein (CRP) levels. Serum TIMP-1 showed correlation with PUCAI, Paris Classification, CRP levels and the erythrocyte sedimentation rate. Serum and faecal levels of MMP-9 and TIMP-1 are useful in discriminating UC patients and non-invasive assessments of disease phenotypes. It seemed that simultaneous measurement of these proteins in combination with other common markers of inflammation could be applied in clinical practice.

Citing Articles

iTRAQ-based proteomic analysis of imiquimod in the treatment of ulcerative colitis.

Guo J, Chen N, Tan F, Zhou J, Xiang H, Luo Y Am J Transl Res. 2023; 15(7):4454-4466.

PMID: 37560232 PMC: 10408506.


How to place the duality of specific MMP-9 inhibition for treatment of inflammatory bowel diseases into clinical opportunities?.

Opdenakker G, Vermeire S, El-Asrar A Front Immunol. 2022; 13:983964.

PMID: 36164340 PMC: 9509204. DOI: 10.3389/fimmu.2022.983964.

References
1.
Shamseya A, Hussein W, Elnely D, Adel F, Header D . Serum matrix metalloproteinase-9 concentration as a marker of disease activity in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2021; 33(1S Suppl 1):e803-e809. DOI: 10.1097/MEG.0000000000002264. View

2.
Sengupta N, MacDonald T . The role of matrix metalloproteinases in stromal/epithelial interactions in the gut. Physiology (Bethesda). 2007; 22:401-9. DOI: 10.1152/physiol.00027.2007. View

3.
Chen C, Huang J, Chang C, Kong M . Fecal calprotectin as a correlative marker in clinical severity of infectious diarrhea and usefulness in evaluating bacterial or viral pathogens in children. J Pediatr Gastroenterol Nutr. 2012; 55(5):541-7. DOI: 10.1097/MPG.0b013e318262a718. View

4.
Turner D, Ricciuto A, Lewis A, DAmico F, Dhaliwal J, Griffiths A . STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2020; 160(5):1570-1583. DOI: 10.1053/j.gastro.2020.12.031. View

5.
Kofla-Dlubacz A, Matusiewicz M, Krzesiek E, Noga L, Iwanczak B . Metalloproteinase-3 and -9 as novel markers in the evaluation of ulcerative colitis activity in children. Adv Clin Exp Med. 2014; 23(1):103-10. DOI: 10.17219/acem/37031. View